Navigation Links
Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
Date:5/22/2012

report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

COMPANY CONTACT: 
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3414
cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
3. Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
4. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel
5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
6. Vanda Pharmaceuticals Appoints Chief Commercial Officer
7. Vanda Pharmaceuticals to Participate in UBS Global Life Sciences Conference
8. Vanda Pharmaceuticals to Participate in Stifel Nicolaus Global Healthcare Conference and Jefferies Fall 2011 Mid-Atlantic Corporate Access Day
9. Vanda Pharmaceuticals Reports Second Quarter 2011 Results
10. Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
11. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanapt™ in Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
(Date:12/24/2014)... Pa. , Dec. 24, 2014  Commonwealth Cornerstone Group ... Markets Tax Credits transaction on Tuesday to help fund the ... Network (PHN) in Sharon . ... in Pennsylvania . It is the largest ... with more than 150 people on staff. Currently, ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
... BRUNSWICK, N.J. and LEIDEN, Netherlands, Feb. 22, 2011 Johnson ... (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) ... offer for Crucell N.V. (Crucell) and has declared the offer ... center for vaccines within the Johnson & Johnson pharmaceuticals group. ...
Cached Medicine Technology:Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 2Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 3Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 4Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 5Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 6Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 7Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional 8
(Date:12/25/2014)... 25, 2014 Recently, BellasDress ... all its wedding dresses. BellasDress has chosen their best-selling ... gift choices for the holiday season. , Now, ... suitable wedding gowns here at discount prices. The business ... at its website. , “All our elegant ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the ... the business has introduced its new collection of 2015 ... , The new prom outfits are guaranteed to contain ... They are specially designed for 2015. Anyone who wants ... visit its website before Jan. 26, 2015, the deadline ...
(Date:12/25/2014)... Santa Rosa, CA (PRWEB) December 25, 2014 ... emergency department visits and 2 million hospital admissions across ... Control and Prevention ). The CDC’s National Hospital ... emergency departments through a survey conducted in 2010. They ... emergency department visits that resulted in a primary diagnosis ...
(Date:12/24/2014)... 24, 2014 Connie Casad, MD, a ... medicine advocate with 30 years of practice experience in ... the health benefits of dietary detoxification. The second study ... following excellent results from test patients who just completed ... explain her interest in conducting the study, Dr. Casad ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... coaches , SUNDAY, Aug. 30 (HealthDay News) -- Young ... major heat injury and illness if they push themselves ... , "Football might get the most attention for severe ... sports is very real," Michael F. Bergeron, a youth-sports ...
... , WILMINGTON, Del., Aug. 30 AstraZeneca (NYSE: ... to head trial, PLATO (A Study of Plat elet Inhibition ... achieved greater efficacy in the primary endpoint, reduction of cardiovascular events ... 12 months; 16% RRR; 95% CI, 0.77 to 0.92; p < ...
... British study finds a reduced risk of stroke afterwards ... results from the longest-running study yet confirm that surgery ... by blockage of the carotid artery, the largest vessel ... endovascular treatment [angioplasty], surgical patients had about half the ...
... , , BEVERLY ... pioneering medical opiate detoxification procedure, offers one of the ... and advanced technology to treat dependencies to Benzodiazepines, including ... of Accelerated Benzodiazepine Neuro-Regulation (ABNR) involves a safe, medically-assisted ...
... Previously Distributed Tablets Expire Aug. 31; New Tablets Available ... 28 The Department of Health will provide free potassium iodide, or KI, ... five nuclear power plants beginning next month. , , ... Aug. 31 and should be discarded in the trash. The pills should not ...
... , PITTSBURGH, Aug. 28 Children,s Hospital of ... healthcare research organization, as the leader in its use of ... , , KLAS interviewed leaders at virtually ... nurses actively using commercially available software to order and chart ...
Cached Medicine News:Health News:Young Athletes at Risk of Heat Injury 2Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 2Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 3Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 4Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 5Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 6Health News:Surgery Better Than Angioplasty for Narrowed Neck Artery 2Health News:Surgery Better Than Angioplasty for Narrowed Neck Artery 3Health News:Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 2Health News:Waismann Method Offers Safe Treatment for Dependency to Benzodiazepines 3Health News:Pennsylvania Health Department Distributing Potassium Iodide to People Living, Working Near Nuclear Power Plants 2Health News:Pennsylvania Health Department Distributing Potassium Iodide to People Living, Working Near Nuclear Power Plants 3Health News:Children's Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 2Health News:Children's Hospital of Pittsburgh of UPMC Recognized for Deepest Use of Electronic Health Records for a Pediatric Hospital in Nation 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: